Literature DB >> 8426475

Suppression of chronic myelogenous leukemia colony growth by interleukin-4.

Z Estrov1, A B Markowitz, R Kurzrock, M Wetzler, H M Kantarjian, A Ferrajoli, J U Gutterman, M Talpaz.   

Abstract

Interleukin-4 (IL-4) is a cytokine with pleiotropic activities. In normal bone marrow cultures grown in the presence of either granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-3 (IL-3), IL-4 suppresses granulocyte-macrophage colony-forming unit (CFU-GM) proliferation but it enhances the colony-stimulatory effect of granulocyte colony-stimulating factor (G-CSF). We studied the effect of IL-4 on chronic myelogenous leukemia (CML) bone marrow or peripheral blood cells from 30 patients using the CFU-granulocyte-erythrocyte-monocyte-megakaryocyte colony culture assay. In several repetitive experiments, IL-4 inhibited CFU-GM colony replication by 24 to 65% in a dose-dependent fashion at concentrations ranging from 0.01 to 10 micrograms/ml when patients' cells were cultured in the presence of erythropoietin alone or with phytohemagglutinin-conditioned medium, GM-CSF, or IL-3. The addition of 100 U/ml of IL-1 beta to the CML cultures partially reversed the inhibitory effect of IL-4. Incubation of CML low-density peripheral blood cells with IL-4 resulted in down-regulation of IL-1 beta and IL-6 production in three of four samples, suggesting that the suppressive effect of IL-4 is mediated by inhibition of IL-1 and by other mechanisms including inhibition of IL-6 production. In contrast to the stimulatory effect exerted by IL-4 on G-CSF-dependent CFU-GM progenitor proliferation in normal marrow, the addition of IL-4 to CML cultures grown in the presence of G-CSF resulted in a divergent effect: suppression of CML CFU-GM in two, stimulation in three, and no significant effect in two CML patients' samples. It is therefore possible that IL-4 may have an in vivo antiproliferative effect in a subpopulation of CML patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8426475

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  4 in total

Review 1.  Biotherapy of chronic myelogenous leukemia.

Authors:  W E Aulitzky; C Peschel; F Schneller; C Huber
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

2.  Growth factors controlling interleukin-4 action on hematopoietic progenitors.

Authors:  A Ferrajoli; T F Zipf; M Talpaz; E A Felix; Z Estrov
Journal:  Ann Hematol       Date:  1993-12       Impact factor: 3.673

3.  The effect of interleukin-4 with or without mast cell growth factor on peripheral blood granulocyte-macrophage colony-forming cells in healthy controls and in myeloproliferative disorders.

Authors:  T Siitonen; A Zheng; E R Savolainen; P Koistinen
Journal:  Ann Hematol       Date:  1995-04       Impact factor: 3.673

Review 4.  Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future.

Authors:  Valentina R Minciacchi; Rahul Kumar; Daniela S Krause
Journal:  Cells       Date:  2021-01-10       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.